Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kip Nalley

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cell|October 24, 2006
Keeping transcriptional activators under controlThomas Kodadek, Devanjan Sikder, Kip Nalley
Nature|August 25, 2006
Proteolytic turnover of the Gal4 transcription factor is not required for function in vivoKip Nalley, Stephen Albert Johnston, Thomas Kodadek
Molecular Biosystems|October 22, 2008
Phosphorylation of the Gal4 DNA-binding domain is essential for activator mono-ubiquitylation and efficient promoter occupancyAnwarul Ferdous, Melissa O'Neal, Kip Nalley, et al.
Genes & Development|December 15, 2006
The role of the proteasomal ATPases and activator monoubiquitylation in regulating Gal4 binding to promotersAnwarul Ferdous, Devanjan Sikder, Thomas Gillette, et al.
Journal of Clinical Bioinformatics|April 3, 2015
Clinical decision support systems for improving diagnostic accuracy and achieving precision medicineChristian Castaneda, Kip Nalley, Ciaran Mannion, et al.
Science (New York, N.Y.)|January 26, 2008
Concurrent fast and slow cycling of a transcriptional activator at an endogenous promoterTatiana S Karpova, Min J Kim, Corentin Spriet, et al.
Journal of Oncology|July 3, 2013
Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicineK Stephen Suh, Sreeja Sarojini, Maher Youssif, et al.
Journal of Hematology & Oncology|August 31, 2013
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patientsRajendra Gharbaran, Andre Goy, Takemi Tanaka, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2003
Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modificationsBrett R Ullman, Teresa Aja, Thomas L Deckwerth, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2005
Structure-activity relationships within a series of caspase inhibitors. Part 2: Heterocyclic warheadsBrett R Ullman, Teresa Aja, Ning Chen, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cell|October 24, 2006
Keeping transcriptional activators under controlThomas Kodadek, Devanjan Sikder, Kip Nalley
Nature|August 25, 2006
Proteolytic turnover of the Gal4 transcription factor is not required for function in vivoKip Nalley, Stephen Albert Johnston, Thomas Kodadek
Molecular Biosystems|October 22, 2008
Phosphorylation of the Gal4 DNA-binding domain is essential for activator mono-ubiquitylation and efficient promoter occupancyAnwarul Ferdous, Melissa O'Neal, Kip Nalley, et al.
Genes & Development|December 15, 2006
The role of the proteasomal ATPases and activator monoubiquitylation in regulating Gal4 binding to promotersAnwarul Ferdous, Devanjan Sikder, Thomas Gillette, et al.
Journal of Clinical Bioinformatics|April 3, 2015
Clinical decision support systems for improving diagnostic accuracy and achieving precision medicineChristian Castaneda, Kip Nalley, Ciaran Mannion, et al.
Science (New York, N.Y.)|January 26, 2008
Concurrent fast and slow cycling of a transcriptional activator at an endogenous promoterTatiana S Karpova, Min J Kim, Corentin Spriet, et al.
Journal of Oncology|July 3, 2013
Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicineK Stephen Suh, Sreeja Sarojini, Maher Youssif, et al.
Journal of Hematology & Oncology|August 31, 2013
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patientsRajendra Gharbaran, Andre Goy, Takemi Tanaka, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2003
Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modificationsBrett R Ullman, Teresa Aja, Thomas L Deckwerth, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2005
Structure-activity relationships within a series of caspase inhibitors. Part 2: Heterocyclic warheadsBrett R Ullman, Teresa Aja, Ning Chen, et al.
Pageof 2